RPCA
IRLA

Running Point Capital Advisors’s IRulya Therapeutics Inc. Common Stock IRLA Stock Holding History

Running Point Capital Advisors’s Portfolio IRLA Stock Details IRLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-16
Closed -$292K – 155
2021
Q3 		$292K Buy
+16
New +$254K 0.13% 84

Other funds holding IRLA

ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Running Point Capital Advisors's IRLA Position: Q4 2021 in Review

Running Point Capital Advisors sold out of IRulya Therapeutics Inc. Common Stock (IRLA) in Q4 2021, closing a stake of 16 shares — an estimated $292K sold.

Running Point Capital Advisors first reported a position in IRLA in Q3 2021 and held it in 1 quarter. The position peaked at $292K in Q3 2021. 98 funds tracked by Wall St. Rank hold IRLA as of Q4 2021.

  • Running Point Capital Advisors reported no remaining IRulya Therapeutics Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Running Point Capital Advisors sold 16 IRulya Therapeutics Inc. Common Stock shares in Q4 2021, an estimated $292K.
  • Running Point Capital Advisors first reported a position in IRulya Therapeutics Inc. Common Stock in Q3 2021 and held it in 1 quarter.
  • Running Point Capital Advisors's IRulya Therapeutics Inc. Common Stock position peaked at $292K in Q3 2021.
  • 98 funds tracked by Wall St. Rank held IRulya Therapeutics Inc. Common Stock as of Q4 2021.

Based on Running Point Capital Advisors's 13F filing for Q4 2021, filed 10 Feb 2022.